FDA Addresses Pre-Submission Meetings In Draft Guidance
This article was originally published in The Gray Sheet
Executive Summary
With the draft guidelines, FDA takes a step toward fulfilling one of its commitments under the reauthorized device user fee program to establish a more structured process for pre-submission meetings with industry.
You may also be interested in...
Mass-Spec Dx Makers Should Look To FDA's Multiplex, Multivariate Approach For Regulatory Tips
As FDA develops a framework for liquid chromatography-mass spectrometry diagnostics, the agency's previously circulated policies on multiplex test instrument systems and in vitro diagnostic multivariate index assays offer hints as to what LC-MS companies can expect.
FDA MDUFA III Performance, By The Numbers
Here's a snapshot of FDA's current premarket device review activity in seven interactive graphics.
Regulatory Briefs: Pre-Submission Program Final Guidance; FDA Meetings; HHS Health IT Nominations
FDA issues final guidance on its pre-submission program. The agency announced upcoming Gastroenterology and Urology Devices advisory panel meetings and a workshop for its Medical Device Epidemiology Network. More regulatory news.